Highlights
- BluGlass has received new laser purchase orders for testing in quantum sensing and surgical applications
- Orders encompass single-mode devices in 405nm, 420nm and 450nm wavelengths and include first sales of BluGlass’ early prototype high-power 405nm 3W multi-mode laser
- Initial orders being fulfilled, engagement with potential customers progressing
Global semiconductor developer BluGlass Limited (ASX: BLG) has secured two new gallium nitride (GaN) laser purchase orders from a quantum photonics pioneer and a leading medical device manufacturer.
Orders span BluGlass’ 405nm, 420nm, and 450nm GaN laser product suite and include the first order of its early prototype higher-powered 405nm 3W multi-mode lasers in flexible form factors.
BluGlass CEO Jim Haden said, “Our lasers will be used for testing in novel quantum sensing and surgical applications. Our single-mode lasers in violet and blue wavelengths are increasingly sought after as they are ideal for biomedical, robotics, and quantum applications.
“We’re also experiencing strong interest in our advanced roadmaps and higher-powered lasers, securing the first order of 50 alpha 3W multi-mode violet prototypes for deployment in medical applications. Ongoing enhancements to our launched product offering are driving conversion efficiency and reliability improvements. If our alpha lasers test well, then once the Company moves to volume production of more mature devices, these customers have the potential to place large, recurring purchase orders for high-volume applications.”
These initial orders are immaterial from a revenue perspective. The Company has commenced fulfilling customer orders and is in advanced discussions with multiple potential customers across its key market segments.
